Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 1/20 | 0.60 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.60 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.60 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.60 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | CPT2 | P23786 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | ACLY | P53396 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29816178 | 1.00 | HMGCR (0.60) | HMGCRCHRM1TBXA2RADRA1ATET2 | |
| SCHEMBL1357615 | 1.00 | HMGCR (0.60) | HMGCRCHRM1TBXA2RADRA1ATET2 | |
| SCHEMBL61203 | 1.00 | HMGCR (0.60) | HMGCRCHRM1TBXA2RADRA1ATET2 | |
| Phosphine SCHEMBL19031718 | 0.97 | HMGCR (0.57) | HMGCRCHRM1TBXA2RADRA1ATET2 | |
| Citric Acid SCHEMBL6040137 | 0.90 | ALDH1A1 (0.71) | HMGCRCHRM1TBXA2RADRA1ATET2 | |
| Pyruvate SCHEMBL18138375 | 0.90 | TET2 (0.56) | HMGCRCHRM1TBXA2RADRA1ATET2 | |
| Dimethylcarbate SCHEMBL28776372 | 0.88 | TET2 (0.48) | HMGCRCHRM1TBXA2RADRA1ATET2 | |
| SCHEMBL8719594 | 0.81 | TET2 (0.42) | HMGCRCHRM1TBXA2RADRA1ATET2 | |
| SCHEMBL29544360 | 0.81 | TET2 (0.47) | HMGCRCHRM1TBXA2RADRA1ATET2 | |
| SCHEMBL15808791 | 0.81 | OR51E2 (0.54) | HMGCRCHRM1TBXA2RADRA1ATET2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 175 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250100999-A1 | METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2025-03-27 | — | — | US | claimed |
| EP-4253366-A2 | METHODS AND INTERMEDIATES FOR PREPARING A THERAPEUTIC COMPOUND USEFUL IN THE TREATMENT OF RETROVIRIDAE VIRAL INFECTION | Gilead Sciences, Inc. (US) | 2023-10-04 | — | — | EP | claimed |
| US-11760746-B2 | Methods and intermediates for preparing therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2023-09-19 | — | — | US | claimed |
| CN-112055712-B | Methods and intermediates for preparing therapeutic compounds useful in the treatment of retroviral infections | 吉利德科学公司 | 2023-07-14 | — | — | CN | claimed |
| EP-3752496-B1 | METHODS AND INTERMEDIATES FOR PREPARING A THERAPEUTIC COMPOUND USEFUL IN THE TREATMENT OF RETROVIRIDAE VIRAL INFECTION | GILEAD SCIENCES INC (US) | 2023-07-05 | — | — | EP | claimed |
| CN-116286569-A | Method for producing (R) -citramalic acid by whole cell transformation of recombinant bacillus licheniformis | 江南大学 | 2023-06-23 | — | — | CN | claimed |
| US-20220009904-A1 | METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2022-01-13 | — | — | US | claimed |
| US-11117886-B2 | Methods and intermediates for preparing therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2021-09-14 | — | — | US | claimed |
| CN-112055712-A | Processes and intermediates for preparing therapeutic compounds useful in the treatment of retroviral infections | 吉利德科学公司 | 2020-12-08 | — | — | CN | claimed |
| US-20200369647-A1 | METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2020-11-26 | — | — | US | claimed |
| US-10696657-B2 | Methods and intermediates for preparing therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2020-06-30 | — | — | US | claimed |
| US-20190300505-A1 | METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2019-10-03 | — | — | US | claimed |
| CN-109336887-A | A kind of benzimidazole and chiral heterocycle class compound and its preparation method and application | 中山大学 | 2019-02-15 | — | — | CN | claimed |
| CN-106831862-A | Axial chirality monophosphorus ligand of one class chirality bridging and preparation method thereof | 中山大学 | 2017-06-13 | — | — | CN | claimed |
| US-9653307-B1 | Surface modification compositions, methods of modifying silicon-based materials, and methods of forming high aspect ratio structures | MICRON TECHNOLOGY, INC. (US) | 2017-05-16 | — | — | US | claimed |
| US-8460534-B2 | Chromium(VI)-free black passivation of surfaces containing zinc | ATOTECH DEUTSCHLAND GMBH (DE) | 2013-06-11 | — | — | US | claimed |
| EP-1970470-B1 | Chrome(VI)-free black passivates for surfaces containing zinc | ATOTECH DEUTSCHLAND GMBH (DE) | 2011-05-11 | — | — | EP | claimed |
| US-20100133113-A1 | CHROMIUM(VI)-FREE BLACK PASSIVATION OF SURFACES CONTAINING ZINC | ATOTECH DEUTSCHLAND GMBH (DE) | 2010-06-03 | — | — | US | claimed |
| CN-116854630-B | Methods and intermediates for preparing therapeutic compounds useful in the treatment of retroviral infections | 吉利德科学公司 | 2026-05-19 | — | — | CN | disclosed |
| US-5952462-A | Transition state analogs | IGEN INTERNATIONAL INC. (US) | 1999-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190300505-A1 | METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS | CYP11A1, CYP11B1, CYP11B2 | HMGCR 23/4885CHRM1 3948/4885TBXA2R 947/4885 |
| US-20220009904-A1 | METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS | CYP11A1, CYP11B1, CYP11B2 | HMGCR 20/4885CHRM1 3863/4885TBXA2R 873/4885 |
| US-11117886-B2 | Methods and intermediates for preparing therapeutic compounds | CYP11A1, CYP11B1, CYP11B2 | HMGCR 23/4885CHRM1 3948/4885TBXA2R 947/4885 |
| US-10696657-B2 | Methods and intermediates for preparing therapeutic compounds | CYP11A1, CYP11B1, CYP11B2 | HMGCR 23/4885CHRM1 3948/4885TBXA2R 947/4885 |
| US-20250100999-A1 | METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS | CYP11A1, CYP11B1, CYP11B2 | HMGCR 23/4885CHRM1 3948/4885TBXA2R 947/4885 |
| US-11760746-B2 | Methods and intermediates for preparing therapeutic compounds | CYP11A1, CYP11B1, CYP11B2 | HMGCR 20/4885CHRM1 3863/4885TBXA2R 873/4885 |
| US-20200369647-A1 | METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS | CYP11A1, CYP11B1, CYP11B2 | HMGCR 23/4885CHRM1 3948/4885TBXA2R 947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.